Nuveen Asset Management LLC Buys 1,239,185 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Nuveen Asset Management LLC grew its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) by 77.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,835,412 shares of the company’s stock after acquiring an additional 1,239,185 shares during the quarter. Nuveen Asset Management LLC owned 0.16% of Ginkgo Bioworks worth $8,847,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of DNA. ARK Investment Management LLC increased its stake in Ginkgo Bioworks by 45.2% during the 3rd quarter. ARK Investment Management LLC now owns 126,818,856 shares of the company’s stock worth $395,675,000 after purchasing an additional 39,460,799 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its stake in Ginkgo Bioworks by 41.7% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 30,981,948 shares of the company’s stock worth $96,664,000 after purchasing an additional 9,123,775 shares in the last quarter. State Street Corp increased its stake in Ginkgo Bioworks by 210.3% during the 2nd quarter. State Street Corp now owns 12,411,855 shares of the company’s stock worth $29,540,000 after purchasing an additional 8,411,787 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its stake in Ginkgo Bioworks by 201.8% during the 2nd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 3,820,010 shares of the company’s stock worth $9,092,000 after purchasing an additional 2,554,180 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in Ginkgo Bioworks by 131.1% during the 2nd quarter. Renaissance Technologies LLC now owns 3,141,400 shares of the company’s stock worth $7,477,000 after purchasing an additional 1,782,100 shares in the last quarter. 61.83% of the stock is owned by institutional investors.

Insider Activity

In other news, insider Jason R. Kelly sold 258,748 shares of the stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $1.73, for a total value of $447,634.04. Following the completion of the sale, the insider now owns 14,947,040 shares of the company’s stock, valued at approximately $25,858,379.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Jason R. Kelly sold 258,748 shares of the stock in a transaction that occurred on Wednesday, January 25th. The stock was sold at an average price of $1.73, for a total value of $447,634.04. Following the completion of the sale, the insider now owns 14,947,040 shares of the company’s stock, valued at approximately $25,858,379.20. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Reshma P. Shetty sold 98,606 shares of the stock in a transaction that occurred on Monday, December 12th. The shares were sold at an average price of $1.84, for a total value of $181,435.04. Following the completion of the sale, the insider now directly owns 19,415,084 shares of the company’s stock, valued at approximately $35,723,754.56. The disclosure for this sale can be found here. In the last 90 days, insiders sold 4,812,538 shares of company stock valued at $8,334,686. 17.47% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on DNA. Berenberg Bank started coverage on Ginkgo Bioworks in a research note on Monday, November 28th. They set a “buy” rating and a $6.00 target price for the company. BTIG Research decreased their price target on shares of Ginkgo Bioworks from $4.00 to $3.00 in a research note on Sunday, March 5th. Finally, Raymond James decreased their price target on shares of Ginkgo Bioworks from $6.00 to $5.00 and set an “outperform” rating for the company in a research note on Friday, March 3rd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Ginkgo Bioworks presently has a consensus rating of “Hold” and a consensus price target of $4.39.

Ginkgo Bioworks Trading Down 0.8 %

NYSE DNA opened at $1.24 on Friday. The company has a market cap of $2.41 billion, a PE ratio of -0.96 and a beta of 0.91. The company has a current ratio of 11.71, a quick ratio of 11.67 and a debt-to-equity ratio of 0.04. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $1.19 and a 12 month high of $4.91. The stock has a 50 day moving average of $1.69 and a 200-day moving average of $2.19.

Ginkgo Bioworks Company Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.